About AnaptysBio, Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Address: 10421 Pacific Center Court, San Diego, CA, United States, 92121
AnaptysBio, Inc News and around…
Latest news about AnaptysBio, Inc (ANAB) common stock and company :
AnaptysBio Inc(NASDAQ: ANAB) hasannounced updated datafrom the GALLOP Phase 2 trial of imsidolimab in generalized ...
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduction at week 16Phase 3 GEMINI-1 clinical trial has been initiated subsequent to FDA end-of-Phase 2 meeting and FDA orphan drug designation for the treatment of GPPIn addition to GPP, imsidolimab clinical development to foc
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
TheFDA has approved a second indicationforGlaxoSmithKline plc's(NYSE: GSK) Jemperli ...
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
In this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier. If you want to skip our detailed analysis of Frazier’s history and hedge fund performance, go directly to the 5 Best Biotech Stocks to Buy According to Alan Frazier. Alan Frazier established Frazier Healthcare Partners in 1991. During his […]
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
In trading on Monday, shares of AnaptysBio Inc (ANAB) crossed below their 200 day moving average of $24.77, changing hands as low as $24.06 per share. AnaptysBio Inc shares are currently trading off about 6.5% on the day..
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For ...
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...
Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive officers were among those buying shares this past week.
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, ...
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Here are some of the most noteworthy insider purchases that were reported in the past week.
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]
In trading on Thursday, shares of AnaptysBio Inc (ANAB) crossed above their 200 day moving average of $22.44, changing hands as high as $22.66 per share. AnaptysBio Inc shares are currently trading up about 2.7% on the day..
Investors in AnaptysBio Inc (ANAB) saw new options become available this week, for the November 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several ...
This analyst is excited about the company's prospects.
Upgrades Sidoti & Co. upgraded the previous rating for PAR Technology Corp (NYSE:PAR) from Neutral to Buy. For the ...
AnaptysBio, Inc (ANAB) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
